FDA advisers vote against sleep peptide as they debate safety and health claims
The FDA’s advisory committee is meeting for two days to discuss whether seven peptides — which have become popular in wellness circles — should be allowed to be compounded.
The FDA’s advisory committee is meeting for two days to discuss whether seven peptides — which have become popular in wellness circles — should be allowed to be compounded. This story matters for Finance & Markets readers tracking fund. Reported by marketwatch.com. Read the full original at the source link below.
Originally reported by marketwatch.com. FundNews curates and briefs the finance & markets stories that matter. Our editorial policy →